Purpose: Glucose transporter-1 (GLUT-1), a target gene of hypoxia-inducible factor-1, has been considered a candidate endogenous marker of tumor hypoxia. Expression of GLUT-1 may also serve as an indicator for the induction of the transcriptional response to hypoxia, which has been linked to enhanced proliferation, resistance to therapy, and metastatic propagation of cancer cells. Overexpression of GLUT-1 has been shown to correlate with poor prognosis in several tumor entities, among them cancers of the uterine cervix. The validity of these hypotheses is investigated.

Experimental Design: The expression of GLUT-1 was assessed in 80 biopsies of Eppendorf oxygenation measurement tracks from locally advanced cervical cancers in 47 patients using immunohistochemistry.

Results: No correlation was found between the expression of GLUT-1 and oxygenation variables (median pO2, HF 2.5 and HF 5). Expression of GLUT-1 was found greater in larger tumors (P = 0.0001) and to exhibit a linear increase with Fédération Internationale de Gynécologie et d' Obstétrique stage (P = 0.002). Overall survival (P = 0.004) and recurrence-free survival (P = 0.007) were significantly shorter for patients with expression of GLUT-1. In the subgroup of patients treated with surgery, this effect on prognosis was not independent when pT stage or pN stage were included in a multivariate Cox proportional hazards model.

Conclusions: The suitability of GLUT-1 as an endogenous marker of tumor hypoxia seems questionable. The association with prognosis may partially depend on confounding factors.

Under physiologic conditions, glucose transporter-1 (GLUT-1) is expressed most strongly in erythrocytes and blood-brain or blood-nerve barriers (13). Overexpression of GLUT-1 is found in many types of solid malignancies (1), among them cancers of the uterine cervix (4). Overexpression of GLUT-1 significantly contributes to the phenomenon of increased glucose uptake (as measured by positron emission tomography imaging of 18F-fluorodeoxyglucose uptake) found in solid tumors which can also be exploited for diagnostic purposes (5, 6). Because expression of GLUT-1 is stimulated by hypoxia via activation of the hypoxia-inducible factor-1 (HIF-1; ref. 7), the question arises as to whether GLUT-1 expression in malignant tissue can be used as a surrogate measure of tissue oxygen (O2) depletion and could thus serve as an endogenous marker of tumor hypoxia.

Hypoxia is a hallmark of solid tumors and has an effect both on the effectiveness of cancer treatment and on the aggressive traits of malignant cells. Reduced O2 availability diminishes the efficacy of ionizing radiation (8). Significantly higher radiation doses are thus needed in hypoxic tissue to achieve equivalent cytotoxic effects compared with normoxic microenvironments. Additionally, severely hypoxic conditions (<0.1% O2) can promote the accumulation of genomic mutations (911) and may thus expedite malignant progression (e.g., via activation of oncogenes or inactivation of tumor suppressor genes). Hypoxia also has a profound effect on gene expression (termed “hypoxic response”; e.g., ref. 12), which is mediated via oxygen-regulated transcription factors (13), among which HIF-1 occupies a pivotal position. GLUT-1 is one member of the broad range of target genes of HIF-1 which are believed to confer enhanced cell survival and proliferation under hypoxic conditions (for a recent review, see ref. 7) and are thus viewed as driving factors for tumor growth, at least when a net effect is considered. Consistent with such a concept, overexpression of GLUT-1 has been shown to be associated with an adverse prognosis in several tumor entities (1423), among them cancers of the uterine cervix (4). The present study examined the possibility of assessing GLUT-1 expression to gain information on the extent of tumor hypoxia. Additionally, the role of GLUT-1 as a prognostic factor was assessed in this cohort of patients with long-term follow-up.

Patients. All patients in this study were enrolled in a prospective clinical trial for the evaluation of the significance of tumor oxygenation in primary, locally advanced carcinomas of the uterine cervix that commenced at the Department of Obstetrics and Gynecology, University of Mainz Medical School, in June 1989. The study design was approved by the local Medical Ethics Committee, with patients giving informed written consent before being enrolled. All 47 patients from the former study, for whom one or two tumor biopsy specimens of the oxygen measurement tracks were available, were included in the present study. Patients of this subgroup had been recruited between August 1991 and April 1997. Table 1 shows relevant patient and tumor characteristics at the time of pretreatment oxygen tension (oxygen partial pressure, pO2) measurements.

Table 1.

Patient and tumor characteristics at the time of pretherapeutic oxygen tension measurements

No. patientsMedianRange
FIGO stages    
    IB   
    IIA   
    IIB 26   
    IIIA   
    IIIB 9 (6)   
    IVA 2 (0)   
    IVB   
Grading    
    1 7 (6)   
    2 19 (17)   
    3 14 (13)   
    ND 7 (6)   
pT stages    
    pT1b   
    pT2a   
    pT2b 20   
    pT3b   
    NA 17 (12)   
pN stages    
    N0 10   
    N1 18   
    NX   
    NA 17 (12)   
Largest tumor diameter (mm)  60 (50) 0-150 (0-80) 
Menopausal status    
    Premenopausal 24 (23)   
    Postmenopausal 23 (19)   
Patient age (y)    
    <55 27 (26) 52 26-80 
    ≥55 20 (16)   
Hemoglobin concentration (g/dL)    
    <12 g/dL 13 (11) 12.8 (12.9) 9.3-16.4 
    ≥12 g/dL 33 (31)   
    ND 1 (0)   
No. patientsMedianRange
FIGO stages    
    IB   
    IIA   
    IIB 26   
    IIIA   
    IIIB 9 (6)   
    IVA 2 (0)   
    IVB   
Grading    
    1 7 (6)   
    2 19 (17)   
    3 14 (13)   
    ND 7 (6)   
pT stages    
    pT1b   
    pT2a   
    pT2b 20   
    pT3b   
    NA 17 (12)   
pN stages    
    N0 10   
    N1 18   
    NX   
    NA 17 (12)   
Largest tumor diameter (mm)  60 (50) 0-150 (0-80) 
Menopausal status    
    Premenopausal 24 (23)   
    Postmenopausal 23 (19)   
Patient age (y)    
    <55 27 (26) 52 26-80 
    ≥55 20 (16)   
Hemoglobin concentration (g/dL)    
    <12 g/dL 13 (11) 12.8 (12.9) 9.3-16.4 
    ≥12 g/dL 33 (31)   
    ND 1 (0)   

NOTE: Numbers in brackets indicate deviations for the subgroup of patients treated with curative intent (survival correlations).

Abbreviations: ND, not documented; NA, not applicable, no surgical treatment (radiation only).

For correlations involving survival, only patients treated with curative intent were included (n = 42). In 31 of these, the primary therapy was surgical. Abdominal radical hysterectomy and pelvic/periaortic lymph node dissection was the standard surgical procedure. In 5 of 31 patients, supralevator exenteration had to be done instead of radical hysterectomy. The remaining 11 cases were treated by radiation instead of surgery because their tumors were fixed to the pelvic wall or their comorbidity excluded extensive operations. Primary radiotherapy was given as combined teletherapy and brachytherapy. External beam irradiation was applied with 10 MV photons produced by a linear accelerator at the Division of Radiotherapy. For brachytherapy, a high–dose rate 192Ir afterloading machine at the Department of Obstetrics and Gynecology was used (for details, see ref. 24). Adjuvant chemotherapy regimens are described in detail in Ref. 31. Median follow-up time was 28 months (SD 28), ranging from 4 to 95 months.

Tumor oxygen tension measurements. Tumor pO2 was measured pretherapeutically with the computerized Eppendorf histography system (Eppendorf, Hamburg, Germany), using a protocol that has been described in detail previously (25). Briefly, pO2 readings were done in the conscious patient along linear tracks, first in the s.c. fat of the mons pubis followed by cervical measurements at the 12 and 6 o'clock sites in macroscopically vital tumor tissue. Within the tumor tissue, up to 35 pO2 measurements were made along each electrode track (70 readings in total) starting at a tissue depth of 5 mm. The individual pO2 measurement points were situated 0.7 mm apart, resulting in an overall measurement track length of ∼25 mm. Immediately following pO2 measurements, needle core biopsies (obtained using Biopty, Radioplast, Uppsala, Sweden) of ∼2 mm in diameter and 20 mm in length were taken from those tumor areas where pO2 readings had been obtained. Both the pO2 readings and the needle core biopsies were done without general anesthesia in all patients. Intravaginal temperature, arterial blood pressure, heart rate, hemoglobin concentration, hematocrit, and arterial oxyhemoglobin saturation were monitored at the time when pO2 readings were taken. The pretherapeutic pO2 measurements were usually done 1 to 5 days before oncological treatment. After histologic examination of the biopsy specimens, pO2 measurements in necrotic tissue areas were excluded from analysis.

Immunohistochemistry. Expression of GLUT-1 was assessed in 80 biopsy specimens taken from the tumor pO2 measurement tracks obtained directly after pO2 measurement in 47 patients. Two biopsies, corresponding to the 6 and 12 o'clock positions of the tumor center were available for each of 33 patients and one biopsy for each of the remaining 14 cases. All material was fixed in formalin before being embedded in paraffin. Histologic slides were prepared from the paraffin blocks and dried overnight at 37°C. Subsequently, specimens were dewaxed in two changes of fresh xylene and rehydrated in a descending alcohol series. Retrieval of antigenic binding sites was done by heating specimens in 10 mmol/L citrate buffer (pH 6.0) in a microwave oven for 17 minutes. GLUT-1 polyclonal rabbit anti-human GLUT-1 clone MYM (DakoCytomation, Hamburg, Germany) was used as the primary antibody at a concentration of ∼1 μg/mL in antibody diluent (DakoCytomation, 1:200 dilution). Incubation took place overnight at 4°C. A biotinylated goat anti-mouse/rabbit secondary antibody was applied for 30 minutes at room temperature and further detection was carried out using a streptavidin-biotin-horseradish peroxidase system (Duet-Kit, DakoCytomation), in accordance with the manufacturer's instructions. Negative control specimens were treated with antibody diluent without the primary antibody under the same conditions. Slides were counterstained with Mayer's hematoxylin, dehydrated in an ascending alcohol series and covered with a coverslip using Eukitt mounting medium (Riedel-de Haen, Seelze, Germany).

Assessment of GLUT-1 expression. A semiquantitative scoring system was used to assess the degree of GLUT-1 expression in entire biopsy sections: score 0, no staining or only very few positive cells (“absent”); score 1, <10% positive (“weak”), score 2, 11% to 50% positive (“moderate”); score 3, >50% positive (“strong”). Each specimen was scored by two independent observers (A.M. and A.W.). Discordant cases were reevaluated and discussed using a conference microscope.

Statistical analysis. All statistical tests were done using the SPSS software package (version 11.5; SPSS, Inc., Chicago, IL). The significance level was set at α = 5% for all comparisons. Linear correlations between two variables were described by Spearman's rank correlation coefficient (ρ). Two-sided Mann Whitney U tests and Kruskal Wallis tests were used for comparison of categorized variables. Survival estimates were calculated using the Kaplan-Meier method and differences between groups were assessed with log-rank statistics. The Cox proportional hazards model was used for the multivariate analysis of the effect of individual factors on survival.

GLUT-1 expression. GLUT-1 expression exhibited a characteristic pattern, with staining intensity increasing as a function of distance from the vascularized tumor stroma (Fig. 1), being particularly strong in the viable cell layers immediately adjacent to necrotic areas. Erythrocytes and perineural tissue invariably stained positive. Variation of erythrocyte staining intensity was very low, indicating a neglectable batch to batch variation in overall GLUT-1 immunoreactivity. No positive staining was seen in the vascular tumor stroma. GLUT-1 expression was present in 59 of 80 biopsies (∼74%). Of these, GLUT-1 expression was weak in 37 cases (∼63%), moderate in 18 cases (∼30%), and strong in four cases (∼7%).

Fig. 1.

Expression patterns and score of GLUT-1 expression (histologic photographs, 20× magnification) with respective oxygen tension (pO2) histograms for hypoxic (top) and normoxic tumors (bottom). Examples of high and low expression of GLUT-1 are depicted; n = number of pO2 readings in the respective measurement track. Note that positive staining (bottom right) is found almost entirely in erythrocytes.

Fig. 1.

Expression patterns and score of GLUT-1 expression (histologic photographs, 20× magnification) with respective oxygen tension (pO2) histograms for hypoxic (top) and normoxic tumors (bottom). Examples of high and low expression of GLUT-1 are depicted; n = number of pO2 readings in the respective measurement track. Note that positive staining (bottom right) is found almost entirely in erythrocytes.

Close modal

GLUT-1 expression, clinical, and pathohistologic data. GLUT-1 expression increased linearly with Fédération Internationale de Gynécologie et d' Obstétrique (FIGO) stage (r = 0.35, P = 0.002; see Fig. 2). Significantly higher expression of GLUT-1 was also found in larger tumors (r = 0.42, P = 0.0001) and in tumors with a higher pT stage (r = 0.34, P = 0.015). GLUT-1 expression showed no correlation with histologic grading, pN stage, patient age, parity, and pretherapeutic hemoglobin level.

Fig. 2.

GLUT-1 score as a function of FIGO stage (significantly positive correlation, P < 0.002).

Fig. 2.

GLUT-1 score as a function of FIGO stage (significantly positive correlation, P < 0.002).

Close modal

GLUT-1 expression and oxygenation data. The Kruskal-Wallis test showed no differences in median pO2, hypoxic fraction ≤2.5 mm Hg (HF 2.5) and hypoxic fraction ≤5 mm Hg (HF 5) between the four GLUT-1 expression scores. There were also no statistically significant differences in GLUT-1 expression between individual categories (e.g., absent expression versus strong expression; Fig. 3). A subgroup analysis of squamous cell carcinomas only (n = 60) also showed no differences in any of the oxygenation variables between the four classes of intensity of GLUT-1 expression. A weak trend (r = 0.34; P = 0.14, n = 20) was seen for higher values of HF 5 in non–squamous cell histology cases with higher GLUT-1 expression. As Fig. 3 shows, some severely hypoxic tumors had weak to absent expression of GLUT-1 and normoxic tumors repeatedly showed moderate to strong GLUT-1 expression.

Fig. 3.

Fraction of pO2 readings ≤5 mm Hg (HF 5) and GLUT-1 scores in identical microareas of locally advanced cancers of the uterine cervix. Note that some circles represent more than one measurement.

Fig. 3.

Fraction of pO2 readings ≤5 mm Hg (HF 5) and GLUT-1 scores in identical microareas of locally advanced cancers of the uterine cervix. Note that some circles represent more than one measurement.

Close modal

GLUT-1 expression and survival. Univariate Kaplan-Meier survival analysis showed significantly improved overall (P = 0.004) and recurrence-free (P = 0.007) survival for patients whose tumors entirely lacked (both biopsies negative in cases where two biopsies were available) expression of GLUT-1 (see Fig. 4). In addition, correlations with poorer overall and recurrence-free survival, respectively, were found for the presence of lymph node metastasis (P = 0.0002 and P = 0.0001), higher pT stage (P = 0.02 and P = 0.0367) and higher FIGO stage (P = 0.0067 and P = 0.0248). When either pT stage or pN stage were included in a multivariate Cox proportional hazards analysis (only applicable in cases treated with surgery), there was no significant independent influence of GLUT-1 expression on prognosis. Only pN stage remained a significant prognostic factor for overall (P = 0.015) and recurrence-free (P = 0.007) survival.

Fig. 4.

Kaplan-Meier plots for overall (top) and recurrence-free (bottom) survival of GLUT-1-negative and GLUT-1-positive cases.

Fig. 4.

Kaplan-Meier plots for overall (top) and recurrence-free (bottom) survival of GLUT-1-negative and GLUT-1-positive cases.

Close modal

The primary aim of this study was to evaluate the suitability of GLUT-1 as an endogenous marker of tumor hypoxia. The expression of GLUT-1 was analyzed using immunohistochemistry in biopsy specimens taken from oxygenation measurement tracks done with the Eppendorf microsensor system. The fact that both measurements originate from identical tissue microareas is a novel feature of this study. Using this methodology, no correlation of GLUT-1 expression and oxygenation variables (median pO2, HF 2.5 and HF 5) were found. Several severely hypoxic tissue biopsies showed weak or no expression of GLUT-1, whereas moderate to strong expression was repeatedly found in normoxic specimens. In a recent study, Airley et al. (4) described a weak, albeit statistically significant, correlation of higher GLUT-1 expression in cases with higher values of HF 2.5. This finding may in the first instance be interpreted as being contradictory to our results. On closer examination however, the suitability of GLUT-1 as an endogenous hypoxia marker seems highly questionable from the data of both studies. In agreement with our own results, Airley et al. (4) found no correlation of GLUT-1 expression with HF 5 and the study also does not mention a correlation with the median pO2. Both studies show that GLUT-1 expression may be absent in a significant amount of severely hypoxic tumors and that well-oxygenated tumors may exhibit very strong expression of GLUT-1. Two recent studies compared GLUT-1 (and carbonic anhydrase IX) expression with the accumulation of the “hypoxia-marker” pimonidazole and found a strong spatial colocalization and correlation between the two variables, concluding that both proteins may be regarded as endogenous hypoxia markers (17, 26). This interpretation is problematic since pimonidazole, as well as another “extrinsic” hypoxia marker, EF5, have been shown not to correlate with the oxygenation status, as directly measured with microelectrodes (2730). It also has to be kept in mind that prognostic correlations have thus far only been shown for the “snapshot” picture of hypoxia acquired with the Eppendorf microsensor technique, assessing all pathophysiologically relevant types of hypoxia (acute and chronic), provided measurements in necrotic tissue areas can be excluded as done in our study. Similar to our findings, Hedley et al. (31) in a recent study found no correlation between a further HIF-1α target gene, carbonic anhydrase IX, and the oxygenation status measured by microelectrodes in cervical cancers. Applying the same experimental setup as that used in this study, we recently showed that there is also no direct correlation between HIF-1α expression and oxygenation status in squamous cell carcinomas of the uterine cervix (32). HIF-1α data originating from this former study were available for most of the cases reported in the present study and a preliminary analysis revealed no correlation between the two proteins. However, these data are not shown, because the methods for assessment were different and the two markers were not always analyzed in consecutive sections.

Expression of GLUT-1, much like HIF-1α, is induced by a variety of stimuli besides hypoxia. For GLUT-1, established inducing factors are glucose deprivation (33), oncogenic transformation (e.g., overexpression of c-MYC; ref. 34), inhibition of oxidative phosphorylation (35), angiotensin II (in mesangial cells; ref. 36), and osmotic stress (37, 38). According to our interpretation of the data, induction of HIF-1α and subsequent transactivation of GLUT-1 by hypoxia, although undoubtedly present, cannot be selectively identified due to the heterogeneous occurrence of the other abovementioned factors in human cancer specimens.

Another important issue is the prognostic effect of GLUT-1 as a marker of the hypoxic response. In univariate analysis, an improved overall and recurrence-free survival in patients with completely absent GLUT-1 expression (i.e., two negative biopsies) was found. Multivariate Cox regression analysis revealed that both correlations were independent of FIGO stage, clinical tumor size, histologic grading, patient age, and pretherapeutic hemoglobin concentration. Inclusion of pT stage or pN stage into the model, however, abrogated the independent prognostic effect of GLUT-1 expression. The dependency of the prognostic relevance of GLUT-1 expression on T stage and N stage has been described for other tumor entities (e.g., breast carcinoma; ref. 23) and colorectal cancer (16, 22). The only study that evaluated the prognostic effect of GLUT-1 expression in cancers of the uterine cervix found a significant correlation with prognosis only for metastasis-free survival. A possible dependency of this correlation on nodal status could not be analyzed, as only patients treated with radiotherapy were examined (4).

A remarkable finding in the present study is the correlation of GLUT-1 expression with FIGO stage, T stage, and maximum clinical tumor size. Correlations between GLUT-1 expression and tumor size have also been described by others (14, 3941) and may have important pathophysiologic implications. Because it is known (24) that tumor oxygenation is independent of tumor size, the finding is consistent with a partial GLUT-1 activation by factors other than hypoxia. Because the expression pattern of GLUT-1 shows increasing intensity towards areas of necrosis and with increasing distance from the stroma (containing the microvessels), it is probable that environmental factors (e.g., glucose deprivation) are important for the expression of the protein. Activated oncogenes may have an effect on the degree of activation by these factors. This influence is likely to become more relevant in higher stages and larger tumors, because oncogenic mutations, accumulated during malignant progression, may become more prevalent.

In conclusion, from the data of the present study as well as from recent findings by other groups, the role of GLUT-1 as an endogenous marker of tumor hypoxia is questionable, at least for cancers of the uterine cervix. There is an association of GLUT-1 expression with prognosis, although correlations were not independent, but instead were due to the association of GLUT-1 expression with established factors of dominant prognostic relevance.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Prof. Dr. M.A. Konerding (Department of Anatomy, University of Mainz) for providing the DISKUS image acquisition system, Beate Köhler for excellent technical assistance, and Dr. Debra K. Kelleher for her valuable assistance in preparing this article.

1
Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers.
Cancer Res
1996
;
56
:
1164
–7.
2
Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative Western blotting and in situ hybridization.
J Biol Chem
1990
;
265
:
18035
–40.
3
Froehner SC, Davies A, Baldwin SA, Lienhard GE. The blood-nerve barrier is rich in glucose transporter.
J Neurocytol
1988
;
17
:
173
–8.
4
Airley R, Loncaster J, Davidson S, et al. Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix.
Clin Cancer Res
2001
;
7
:
928
–34.
5
Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
Int J Cancer
2004
;
109
:
926
–32.
6
Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.
J Clin Oncol
2002
;
20
:
379
–87.
7
Semenza GL. Targeting HIF-1 for cancer therapy.
Nat Rev Cancer
2003
;
3
:
721
–32.
8
Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.
Br J Radiol
1953
;
26
:
638
–48.
9
Yuan J, Narayanan L, Rockwell S, Glazer PM. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH.
Cancer Res
2000
;
60
:
4372
–6.
10
Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment.
Cancer Res
1996
;
56
:
5754
–7.
11
Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs.
Mol Cell
1998
;
2
:
259
–65.
12
Guillemin K, Krasnow MA. The hypoxic response: huffing and HIFing.
Cell
1997
;
89
:
9
–12.
13
Vaupel P, Mayer A, Höckel M. Tumor hypoxia and malignant progression.
Methods Enzymol
2004
;
381
:
335
–54.
14
Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival.
Cancer
2001
;
92
:
634
–41.
15
Cantuaria G, Fagotti A, Ferrandina G, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy.
Cancer
2001
;
92
:
1144
–50.
16
Cooper R, Sarioglu S, Sokmen S, et al. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?
Br J Cancer
2003
;
89
:
870
–6.
17
Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON.
Br J Cancer
2003
;
89
:
1290
–7.
18
Kato H, Takita J, Miyazaki T, et al. Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness.
Anticancer Res
2002
;
22
:
2635
–9.
19
Furudoi A, Tanaka S, Haruma K, et al. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma.
Oncology
2001
;
60
:
162
–9.
20
Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, Airley RE. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies.
Eur J Cancer
2004
;
40
:
503
–7.
21
Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival.
Cancer
1997
;
80
:
1046
–51.
22
Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis.
Cancer
1998
;
83
:
34
–40.
23
Kang SS, Chun YK, Hur MH, et al. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma.
Jpn J Cancer Res
2002
;
93
:
1123
–8.
24
Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix.
Cancer Res
1996
;
56
:
4509
–15.
25
Höckel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements.
Cancer Res
1991
;
51
:
6098
–102.
26
Airley RE, Loncaster J, Raleigh JA, et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.
Int J Cancer
2003
;
104
:
85
–91.
27
Nordsmark M, Loncaster J, Aquino-Parsons C, et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas.
Radiother Oncol
2003
;
67
:
35
–44.
28
Nordsmark M, Loncaster J, Chou SC, et al. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma.
Int J Radiat Oncol Biol Phys
2001
;
49
:
581
–6.
29
Olive PL, Banath JP, Aquino-Parsons C. Measuring hypoxia in solid tumours: is there a gold standard?
Acta Oncol
2001
;
40
:
917
–23.
30
Evans SM, Judy KD, Dunphy I, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding.
Cancer Res
2004
;
64
:
1886
–92.
31
Hedley D, Pintilie M, Woo J, et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas.
Clin Cancer Res
2003
;
9
:
5666
–74.
32
Mayer A, Wree A, Höckel M, Leo C, Pilch H, Vaupel P. Lack of correlation between expression of HIF-1α protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix.
Cancer Res
2004
;
64
:
5876
–81.
33
Boado RJ, Pardridge WM. Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis-acting regulatory element.
J Neurochem
2002
;
80
:
552
–4.
34
Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc.
J Biol Chem
2000
;
275
:
21797
–800.
35
Behrooz A, Ismail-Beigi F. Dual control of glut1 glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation.
J Biol Chem
1997
;
272
:
5555
–62.
36
Nose A, Mori Y, Uchiyama-Tanaka Y, et al. Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: involvement of HB-EGF and EGF receptor transactivation.
Hypertens Res
2003
;
26
:
67
–73.
37
Barnes K, Ingram JC, Porras OH, et al. Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK).
J Cell Sci
2002
;
115
:
2433
–42.
38
Hwang DY, Ismail-Beigi F. Stimulation of GLUT-1 glucose transporter expression in response to hyperosmolarity.
Am J Physiol Cell Physiol
2001
;
281
:
C1365
–72.
39
Yen TC, See LC, Lai CH, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.
J Nucl Med
2004
;
45
:
22
–9.
40
Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases.
Clin Cancer Res
1996
;
2
:
1151
–4.
41
Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage.
Mod Pathol
1998
;
11
:
437
–43.